Moclobemide (Aurorix) in primary major depression.
1. Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors. 2. Aurorix was given per os in an open clinical trial for 6 weeks to 30 patients with DSM-III diagnoses of (nonpsychotic, nonmelancholic), major depression. 3. Out of the 25 patients who completed the study 14 (56%) were responders and 11 (44%) non-responders. 4. The patients tolerated the drug very well, and no serious side-effects were noted. 5. Pretreatment biological markers (dexamethasone suppression test, platelet-MAO-B activity, 3H-imipramine binding, thyroid function) did not have a predictive value regarding the drug response.